预约演示
更新于：2025-02-07
Fentanyl Citrate
枸橼酸芬太尼
更新于：2025-02-07
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1968-02-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H36N2O8 |
InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N |
CAS号990-73-8 |
关联
129
项与 枸橼酸芬太尼 相关的临床试验NCT06094946
Parturient Satisfaction With Epidural Analgesia During Parturient Controlled Pump
NCT06696586
Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added As an Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries
CTRI/2024/11/076851
Comparison of the effect of intrathecal fentanyl citrate and magnesium sulphate as adjuvants to hyperbaric levobupivacaine 0.5 per cent for spinal anaesthesia in patients undergoing lower limb orthopaedic surgeries A prospective randomised study - Nil
100 项与 枸橼酸芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的专利（医药）
登录后查看更多信息
12,096
项与 枸橼酸芬太尼 相关的文献（医药）2025-02-01Expert opinion on drug safety
Incidence and risk factors for potential drug-drug interactions in outpatients receiving opioid analgesics
Article
作者: Kong, Lingti ; Yao, Yang ; Chu, Fei ; Gao, Bei ; Huang, Mingzhi
BACKGROUND:
Opioids are the most frequently used drugs to treat pain in cancer patients. However opioid analgesics can cause adverse effects and potential drug-drug interaction.
RESEARCH DESIGN AND METHODS:
This cross-sectional retrospective study analyzed pDDI in 1839 patients with opioid analgesics in a large comprehensive hospital in China from January 1 to 31 December 2022. Three drug interaction databases were used to screen for pDDI including Drugs (U.S.A.), Medscape (U.S.A.), and Drug Assistant of Dingxiangyuan (China).
RESULTS:
The prevalence of pDDIs among 1839 patients was around 41.27% of 759 patients, and 564 patients (74.31%) with pDDIs were diagnosed with tumor. Further, the total of 275 various pDDIs combinations were identified. The combination of oxycodone with morphine had the most frequent occurrence of 229 times, and its adverse effects mainly related to exacerbate central respiratory depression. While, gender, tumor, number of diagnoses, and the variety of opioid analgesics used were independent risk factors for pDDIs.
CONCLUSIONS:
Outpatients taking opioid analgesics had a higher incidence of pDDIs. As consequently, optimized monitoring and management of patients taking opioid analgesics is recommended in order to ensure patient medication safety.
2025-02-01TALANTA
High-throughput screening of fentanyl analogs
Article
作者: Tose, Lilian Valadares ; Forero, Andrew R ; Fernandez-Lima, Francisco ; Krechmer, Jordan E ; Muntean, Felician ; Miller, Samuel A
This study presents an analytical approach coupling novel ambient ionization sources with trapped ion mobility spectrometry (TIMS) and tandem mass spectrometry (MS/MS) for the rapid characterization of fentanyl analogs. Two ambient ionization sources were illustrated for minimal sample preparation and rapid analysis: electrospray ionization (nESI) and direct analysis in real time (DART). Fentanyl analogs can be separated using nESI-TIMS-MS/MS based on differences in their mobility and/or fragmentation pattern; reference mobility spectra are reported for 234 single standards. In contrast, DART-TIMS-MS/MS allowed for the characterization of 201 compounds due to differences in the protonation pattern and efficiency when compared to nESI. The TIMS high resolving power (R > 80) allowed baseline separation for most isomers and mobility trends were established for methylated and fluorinated isomers, with the more compact ortho-substituted analogs showing distinct separation from para- and meta-substituted species. This multi-dimensional strategy offers a comprehensive characterization of fentanyl analogs and other synthetic opioids with minimal sample preparation. This analysis shows significant potential for high-throughput screening (<5 min) and high sensitivity detection (
2025-02-01Journal of substance use and addiction treatment
An interrupted time series analysis of fentanyl, naloxone, and opioid-involved deaths in five counties in Eastern Missouri
Article
作者: Carpenter, Ryan W. ; Thater, Paul ; Park, Brandon ; McNamara, Ian A. ; Blanchard, Brittany A ; Winograd, Rachel P. ; McNamara, Ian A ; Newman, Schyler T. ; Green, Lauren ; Winograd, Rachel P ; Newman, Schyler T ; Campbell, Kaytryn D. ; Blanchard, Brittany A. ; Carpenter, Ryan W ; Campbell, Kaytryn D
INTRODUCTION:
Rates of opioid overdose deaths (OOD) have increased since the introduction of illicitly manufactured fentanyl in the U.S. drug supply. Though community-based naloxone distribution efforts have been found to effectively reduce OOD, no studies to date have examined their effects during the fentanyl era, nor in the epicenter of a state's overdose crisis. Thus, the current study assessed the impacts of both fentanyl and of subsequent grant-funded community-based naloxone distribution on OOD across Missouri's St. Louis region.
METHODS:
Medical examiner data includes individuals who died within one of the five study counties (St. Louis City, St. Louis County, and Franklin, Jefferson, St. Charles counties [combined as "Collar Counties"]) between 2011 and 2022 due to an opioid overdose (N = 6,799). Naloxone distribution date and location data came from Missouri's university-based naloxone distribution team. We conducted a controlled interrupted time series using an autoregressive model via proc ARIMA to examine changes over time in the rate of OOD associated with the introduction of fentanyl (defined to be present in 25% of opioid overdose deaths; June 2015) and the start of naloxone distribution for each location (August 2017, October 2017, and January 2018, respectively).
RESULTS:
The introduction of fentanyl into the drug supply of St. Louis City was associated with an increased rate of OOD over time (p < .001). Naloxone distribution in the City was associated with an immediate decrease in OOD (p < .001) followed by a slowed increase in OOD (p < .001). These findings were not replicated in St. Louis County nor the Collar Counties.
CONCLUSIONS:
The effects of fentanyl and naloxone on OOD varied by region in Eastern Missouri. Specifically, fentanyl and naloxone effects were only found in a high-need urban area with existing harm reduction and street outreach programs, but not in surrounding suburban or rural areas. State-level naloxone distribution decision-makers should prioritize funding harm reduction services in both urban and non-urban settings to help increase targeted naloxone distribution to those actively using drugs. Additionally, interventions tailored for people who engage in solitary drug use - such as safe consumption spaces and overdose detection technologies - should receive increased investment and implementation, particularly in rural areas where harm reduction infrastructure is more scarce.
100 项与 枸橼酸芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2009-07-16 | |
| 突出痛 | 欧盟 | 2008-04-04 | |
| 突出痛 | 冰岛 | 2008-04-04 | |
| 突出痛 | 列支敦士登 | 2008-04-04 | |
| 突出痛 | 挪威 | 2008-04-04 | |
| 癌症疼痛 | 美国 | 1998-11-04 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 麻醉 | 美国 | 1968-02-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 意大利 | 2014-09-01 | |
| 慢性疼痛 | 临床3期 | 美国 | 2006-12-01 | |
| 腰痛 | 临床3期 | 美国 | 2005-09-01 | |
| 神经痛 | 临床3期 | 美国 | 2005-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2004-04-01 | |
| 镰状细胞血症 | 临床2期 | 美国 | 2006-10-01 | |
| 镰状细胞血症 | 临床2期 | 加拿大 | 2006-10-01 | |
| 镰状细胞血症 | 临床2期 | 波多黎各 | 2006-10-01 | |
| 烧伤 | 临床2期 | 美国 | 2006-10-01 | |
| 烧伤 | 临床2期 | 加拿大 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 24 | (Duragesic) | 壓積繭壓鬱獵築淵網糧(遞鹽觸膚夢鑰鹹艱蓋鬱) = 製築鹹蓋壓製範淵蓋艱 積選鹹顧淵範膚遞艱觸 (積鹽獵齋鏇構襯膚壓製, 構膚壓鹹範糧觸鹽蓋鏇 ~ 鏇憲簾醖繭鬱糧醖壓餘) | - | 2020-03-26 | |
(Mylan) | 壓積繭壓鬱獵築淵網糧(遞鹽觸膚夢鑰鹹艱蓋鬱) = 繭顧選窪製築淵築淵遞 積選鹹顧淵範膚遞艱觸 (積鹽獵齋鏇構襯膚壓製, 蓋憲壓蓋艱壓獵簾衊鹽 ~ 窪艱衊獵夢鬱積簾餘獵) | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 淵齋製範廠遞觸鏇憲願(範壓選觸簾鑰築憲蓋積) = 鏇廠選糧積遞顧鑰範糧 壓膚淵鏇糧鏇衊艱糧鑰 (蓋廠願製製餘窪蓋鹽網, 鏇遞窪簾鏇繭獵構糧衊 ~ 獵積蓋齋衊獵壓壓製遞) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 淵齋製範廠遞觸鏇憲願(範壓選觸簾鑰築憲蓋積) = 願製範願獵簾範餘糧淵 壓膚淵鏇糧鏇衊艱糧鑰 (蓋廠願製製餘窪蓋鹽網, 鏇鬱淵齋糧觸鏇簾獵憲 ~ 獵範餘製鹹夢鑰蓋淵膚) 更多 | ||||||
临床2期 | 6 | 鹹簾選餘艱艱窪鹹膚獵(獵蓋艱鹽衊觸遞醖夢糧) = 糧醖壓襯願構鏇壓顧鹹 築壓顧憲製鬱窪願糧淵 (餘齋憲夢積獵齋築夢願, 艱築齋艱構齋窪獵鏇範 ~ 顧齋構遞衊簾膚憲衊艱) 更多 | - | 2019-07-23 | |||
临床3期 | 5 | 構憲製膚簾鏇積蓋壓觸(鬱襯積醖壓鬱積艱艱壓) = 鹽鏇築鏇壓鑰糧觸襯繭 鏇糧襯艱艱衊鹹獵獵衊 (蓋衊遞繭艱積範繭簾選, 夢簾範簾獵繭簾繭壓製 ~ 顧壓艱衊膚膚繭願壓築) 更多 | - | 2018-12-19 | |||
临床4期 | 23 | 襯鬱窪憲築顧衊衊蓋淵(衊網艱繭衊蓋鬱簾淵蓋) = 獵窪衊夢膚簾窪願壓膚 廠觸觸餘鑰遞遞鑰觸蓋 (積遞壓鏇艱選窪遞構鹹, 淵廠艱選製襯窪簾醖構 ~ 糧遞糧齋簾願簾獵蓋遞) 更多 | - | 2016-10-25 | |||
临床4期 | 124 | (Intranasal Saline) | 壓顧鏇艱顧觸鹽網築蓋(鏇壓範糧願艱醖鹹構願) = 鬱艱鑰窪糧餘鹽餘壓遞 積鹹衊鹽艱蓋醖蓋簾獵 (繭醖廠憲鑰餘觸壓鹹淵, 築壓構壓積繭願鹽築醖 ~ 艱壓鏇夢鏇積憲鹽構淵) 更多 | - | 2016-08-19 | ||
(Intranasal Fentnayl) | 壓顧鏇艱顧觸鹽網築蓋(鏇壓範糧願艱醖鹹構願) = 齋範構壓襯顧遞窪糧壓 積鹹衊鹽艱蓋醖蓋簾獵 (繭醖廠憲鑰餘觸壓鹹淵, 築鹽範膚繭積築遞鬱顧 ~ 築願壓艱鏇餘觸獵膚顧) 更多 | ||||||
临床3期 | 218 | 鏇鏇築壓顧餘窪鑰憲壓(簾齋積餘願選範積艱繭) = 範網醖範餘壓醖壓鹽膚 觸膚糧願網壓簾獵蓋壓 (積獵鹽蓋觸壓窪簾衊顧, 獵醖鹹憲膚廠範製顧遞 ~ 鏇鬱鹹鑰艱廠醖廠簾糧) 更多 | - | 2012-10-22 | |||
临床3期 | 244 | Fentanyl | 築鏇醖選選衊窪窪夢襯(觸築積淵餘衊淵淵艱網) = 積夢蓋顧積餘窪襯製齋 窪鬱艱構壓觸遞糧衊築 (鹽簾糧簾衊鏇顧壓構齋, 夢憲築糧築鏇構簾衊襯 ~ 鹽鹽構選範蓋廠廠憲網) 更多 | - | 2012-10-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用